Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation, migration and invasion

Oncotarget

Volumn 6, Issue 18, 2015, Pages 16321-16340

  Chen, Wen Liang ^a,b   Barszczyk, Andrew ^b   Turlova, Ekaterina ^a,b   Deurloo, Marielle ^b   Liu, Baosong ^a,b   Yang, Burton B ^a   Rutka, James T ^a   Feng, Zhong Ping ^b   Sun, Hong Shuo ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Carvacrol; Cell viability; Glioblastoma; Invasion; Migration; TRPM7

Indexed keywords

CARVACROL; CASPASE 3; COFILIN; GELATINASE A; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TRANSIENT RECEPTOR POTENTIAL CHANNEL M7; ACTIN DEPOLYMERIZING FACTOR; ANTINEOPLASTIC AGENT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MMP2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; TERPENE; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; TRPM7 PROTEIN, HUMAN;

ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; GLIOBLASTOMA CELL LINE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MTT ASSAY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; U87 CELL LINE; UPREGULATION; WESTERN BLOTTING; WHOLE CELL PATCH CLAMP; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BIOSYNTHESIS; BRAIN NEOPLASMS; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; GENETICS; GLIOBLASTOMA; METABOLISM; PATCH CLAMP TECHNIQUE; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR INVASION;

ACTIN DEPOLYMERIZING FACTORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CASPASE 3; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLIOBLASTOMA; HEK293 CELLS; HUMANS; MATRIX METALLOPROTEINASE 2; MONOTERPENES; NEOPLASM INVASIVENESS; PATCH-CLAMP TECHNIQUES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRPM CATION CHANNELS;

EID: 84937888059     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3872     Document Type: Article

References (74)

1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology. 2009; 10:459-466.
2. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, Lang FF, McCutcheon IE, Hassenbusch SJ, Holland E, Hess K, Michael C, Miller D and Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001; 95:190-198.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine. 2005; 352:987-996.
4. Chen J and Yakisich JS. Editorial: emerging concepts and therapeutics strategies for the treatment of brain tumors. Anti-cancer agents in medicinal chemistry. 2014; 14:1063-1064.
5. Leon SP, Zhu J and Black PM. Genetic aberrations in human brain tumors. Neurosurgery. 1994; 34:708-722.
6. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM and Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochimica et biophysica acta. 2007; 1773:1263-1284.
7. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA and Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes & development. 2007; 21:2683-2710.
8. Sun HS, Jackson MF, Martin LJ, Jansen K, Teves L, Cui H, Kiyonaka S, Mori Y, Jones M, Forder JP, Golde TE, Orser BA, Macdonald JF and Tymianski M. Suppression of hippocampal TRPM7 protein prevents delayed neuronal death in brain ischemia. Nature neuroscience. 2009; 12:1300-1307.
9. Aarts M, Iihara K, Wei WL, Xiong ZG, Arundine M, Cerwinski W, MacDonald JF and Tymianski M. A key role for TRPM7 channels in anoxic neuronal death. Cell. 2003; 115:863-877.
10. Jin J, Desai BN, Navarro B, Donovan A, Andrews NC and Clapham DE. Deletion of Trpm7 disrupts embryonic development and thymopoiesis without altering Mg2+ homeostasis. Science. 2008; 322:756-760.
11. Lehen'kyi V, Shapovalov G, Skryma R and Prevarskaya N. Ion channnels and transporters in cancer. 5. Ion channels in control of cancer and cell apoptosis. American journal of physiology Cell physiology. 2011; 301:C1281-1289.
12. Guilbert A, Gautier M, Dhennin-Duthille I, Haren N, Sevestre H and Ouadid-Ahidouch H. Evidence that TRPM7 is required for breast cancer cell proliferation. American journal of physiology Cell physiology. 2009; 297:C493-502.
13. Kim BJ, Nah SY, Jeon JH, So I and Kim SJ. Transient receptor potential melastatin 7 channels are involved in ginsenoside Rg3-induced apoptosis in gastric cancer cells. Basic & clinical pharmacology & toxicology. 2011; 109:233-239.
14. Chen JP, Luan Y, You CX, Chen XH, Luo RC and Li R. TRPM7 regulates the migration of human nasopharyngeal carcinoma cell by mediating Ca(2+) influx. Cell calcium. 2010; 47:425-432.
15. Hanano T, Hara Y, Shi J, Morita H, Umebayashi C, Mori E, Sumimoto H, Ito Y, Mori Y and Inoue R. Involvement of TRPM7 in cell growth as a spontaneously activated Ca2+entry pathway in human retinoblastoma cells. Journal of pharmacological sciences. 2004; 95:403-419.
16. Rybarczyk P, Gautier M, Hague F, Dhennin-Duthille I, Chatelain D, Kerr-Conte J, Pattou F, Regimbeau JM, Sevestre H and Ouadid-Ahidouch H. Transient receptor potential melastatin-related 7 channel is overexpressed in human pancreatic ductal adenocarcinomas and regulates human pancreatic cancer cell migration. International journal of cancer Journal international du cancer. 2012; 131:E851-861.
17. Sun Y, Selvaraj S, Varma A, Derry S, Sahmoun AE and Singh BB. Increase in serum Ca2+/Mg2+ ratio promotes proliferation of prostate cancer cells by activating TRPM7 channels. The Journal of biological chemistry. 2013; 288:255-263.
18. Wang J, Xiao L, Luo CH, Zhou H, Hu J, Tang YX, Fang KN and Zhang Y. Overexpression of TRPM7 is associated with poor prognosis in human ovarian carcinoma. Asian Pacific journal of cancer prevention: APJCP. 2014; 15:3955-3958.
19. Yee NS, Kazi AA and Yee RK. Cellular and Developmental Biology of TRPM7 Channel-Kinase: Implicated Roles in Cancer. Cells. 2014; 3:751-777.
20. Parnas M, Peters M, Dadon D, Lev S, Vertkin I, Slutsky I and Minke B. Carvacrol is a novel inhibitor of Drosophila TRPL and mammalian TRPM7 channels. Cell calcium. 2009; 45:300-309.
21. Zierler S, Yao G, Zhang Z, Kuo WC, Porzgen P, Penner R, Horgen FD and Fleig A. Waixenicin A inhibits cell proliferation through magnesium-dependent block of transient receptor potential melastatin 7 (TRPM7) channels. The Journal of biological chemistry. 2011; 286:39328-39335.
22. Hamaguchi Y, Matsubara T, Amano T, Uetani T, Asano H, Iwamoto T, Furukawa K, Murohara T and Nakayama S. Na(+)-independent Mg(2+) transport sensitive to 2-aminoethoxydiphenyl borate (2-APB) in vascular smooth muscle cells: involvement of TRPM-like channels. Journal of cellular and molecular medicine. 2008; 12:962-974.
23. Qin X, Yue Z, Sun B, Yang W, Xie J, Ni E, Feng Y, Mahmood R, Zhang Y and Yue L. Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels. British journal of pharmacology. 2013; 168:1294-1312.
24. Loza-Tavera H. Monoterpenes in essential oils. Biosynthesis and properties. Advances in experimental medicine and biology. 1999; 464:49-62.
25. Baser KH. Biological and pharmacological activities of carvacrol and carvacrol bearing essential oils. Current pharmaceutical design. 2008; 14:3106-3119.
26. Taylor JM, Jenner PM and Jones WI. A Comparison of the Toxicity of Some Allyl, Propenyl, and Propyl Compounds in the Rat. Toxicology and applied pharmacology. 1964; 6:378-387.
27. Dong RH, Fang ZZ, Zhu LL, Ge GB, Cao YF, Li XB, Hu CM, Yang L and Liu ZY. Identification of CYP isoforms involved in the metabolism of thymol and carvacrol in human liver microsomes (HLMs). Die Pharmazie. 2012; 67:1002-1006.
28. Liang CC, Park AY and Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nature protocols. 2007; 2:329-333.
29. Nishida E, Maekawa S and Sakai H. Cofilin, a protein in porcine brain that binds to actin filaments and inhibits their interactions with myosin and tropomyosin. Biochemistry. 1984; 23:5307-5313.
30. Nebl G, Meuer SC and Samstag Y. Dephosphorylation of serine 3 regulates nuclear translocation of cofilin. Journal of Biological Chemistry. 1996; 271:26276-26280.
31. Leng TD, Li MH, Shen JF, Liu ML, Li XB, Sun HW, Branigan D, Zeng Z, Si HF, Li J, Chen J and Xiong ZG. Suppression of TRPM7 Inhibits Proliferation, Migration, and Invasion of Malignant Human Glioma Cells. CNS neuroscience & therapeutics. 2015; 21:252-261.
32. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell. 1994; 78:539-542.
33. Cheng Y, Zhao J, Qiao W and Chen K. Recent advances in diagnosis and treatment of gliomas using chlorotoxin-based bioconjugates. American journal of nuclear medicine and molecular imaging. 2014; 4:385-405.
34. Liu M, Inoue K, Leng T, Guo S and Xiong ZG. TRPM7 channels regulate glioma stem cell through STAT3 and Notch signaling pathways. Cellular signalling. 2014; 26:2773-2781.
35. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, You MJ, Levy DE, Depinho RA and Bonni A. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes & development. 2008; 22:449-462.
36. Choudhary S, Xiao T, Vergara LA, Srivastava S, Nees D, Piatigorsky J and Ansari NH. Role of aldehyde dehydrogenase isozymes in the defense of rat lens and human lens epithelial cells against oxidative stress. Investigative ophthalmology & visual science. 2005; 46:259-267.
37. Rao QX, Yao TT, Zhang BZ, Lin RC, Chen ZL, Zhou H, Wang LJ, Lu HW, Chen Q, Di N and Lin ZQ. Expression and functional role of ALDH1 in cervical carcinoma cells. Asian Pacific journal of cancer prevention: APJCP. 2012; 13:1325-1331.
38. Chan JA, Krichevsky AM and Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer research. 2005; 65:6029-6033.
39. Karkabounas S, Kostoula OK, Daskalou T, Veltsistas P, Karamouzis M, Zelovitis I, Metsios A, Lekkas P, Evangelou AM, Kotsis N and Skoufos I. Anticarcinogenic and antiplatelet effects of carvacrol. Experimental oncology. 2006; 28:121-125.
40. Aydin E, Turkez H and Keles MS. The effect of carvacrol on healthy neurons and N2a cancer cells: some biochemical, anticancerogenicity and genotoxicity studies. Cytotechnology. 2014; 66:149-157.
41. Xu H, Delling M, Jun JC and Clapham DE. Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channels. Nature neuroscience. 2006; 9:628-635.
42. Suo L, Kang K, Wang X, Cao Y, Zhao H, Sun X, Tong L and Zhang F. Carvacrol alleviates ischemia reperfusion injury by regulating the PI3K-Akt pathway in rats. PloS one. 2014; 9:e104043.
43. Yu W, Liu Q and Zhu S. Carvacrol protects against acute myocardial infarction of rats via anti-oxidative and antiapoptotic pathways. Biological & pharmaceutical bulletin. 2013; 36:579-584.
44. Nafees S, Ahmad ST, Arjumand W, Rashid S, Ali N and Sultana S. Carvacrol ameliorates thioacetamideinduced hepatotoxicity by abrogation of oxidative stress, inflammation, and apoptosis in liver of Wistar rats. Human & experimental toxicology. 2013; 32:1292-1304.
45. Dagli Gul AS, Fadillioglu E, Karabulut I, Yesilyurt A and Delibasi T. The effects of oral carvacrol treatment against H2O2 induced injury on isolated pancreas islet cells of rats. Islets. 2013; 5:149-155.
46. Liang WZ and Lu CH. Carvacrol-induced [Ca2+]i rise and apoptosis in human glioblastoma cells. Life sciences. 2012; 90:703-711.
47. Arunasree KM. Anti-proliferative effects of carvacrol on a human metastatic breast cancer cell line, MDA-MB 231. Phytomedicine: international journal of phytotherapy and phytopharmacology. 2010; 17:581-588.
48. Yin QH, Yan FX, Zu XY, Wu YH, Wu XP, Liao MC, Deng SW, Yin LL and Zhuang YZ. Anti-proliferative and pro-apoptotic effect of carvacrol on human hepatocellular carcinoma cell line HepG-2. Cytotechnology. 2012; 64:43-51.
49. Sahai E. Mechanisms of cancer cell invasion. Current opinion in genetics & development. 2005; 15(1):87-96.
50. Friedl P and Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003; 3:362-374.
51. Bailly M and Condeelis J. Cell motility: insights from the backstage. Nature cell biology. 2002; 4:E292-294.
52. Yamaguchi H and Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochimica et biophysica acta. 2007; 1773:642-652.
53. Yamaguchi H and Condeelis J. Regulation of the actin cytoskeleton in cancer cell migration and invasion. Biochimica et biophysica acta. 2007; 1773:642-652.
54. Martoglio AM, Tom BD, Starkey M, Corps AN, Charnock-Jones DS and Smith SK. Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays. Mol Med. 2000; 6:750-765.
55. Unwin RD, Craven RA, Harnden P, Hanrahan S, Totty N, Knowles M, Eardley I, Selby PJ and Banks RE. Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics. 2003; 3:1620-1632.
56. Sinha P, Kohl S, Fischer J, Hutter G, Kern M, Kottgen E, Dietel M, Lage H, Schnolzer M and Schadendorf D. Identification of novel proteins associated with the development of chemoresistance in malignant melanoma using two-dimensional electrophoresis. Electrophoresis. 2000; 21:3048-3057.
57. Gunnersen JM, Spirkoska V, Smith PE, Danks RA and Tan SS. Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expression. Glia. 2000; 32:146-154.
58. Keshamouni VG, Michailidis G, Grasso CS, Anthwal S, Strahler JR, Walker A, Arenberg DA, Reddy RC, Akulapalli S, Thannickal VJ, Standiford TJ, Andrews PC and Omenn GS. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a migratory/invasive phenotype. J Proteome Res. 2006; 5:1143-1154.
59. Wrighton KH. Cytoskeleton: RhoC invades cofilin's space. Nature reviews Molecular cell biology. 2011; 12:346-347.
60. Zebda N, Bernard O, Bailly M, Welti S, Lawrence DS and Condeelis JS. Phosphorylation of ADF/cofilin abolishes EGF-induced actin nucleation at the leading edge and subsequent lamellipod extension. The Journal of cell biology. 2000; 151:1119-1128.
61. Hotulainen P, Paunola E, Vartiainen MK and Lappalainen P. Actin-depolymerizing factor and cofilin-1 play overlapping roles in promoting rapid F-actin depolymerization in mammalian nonmuscle cells. Molecular biology of the cell. 2005; 16:649-664.
62. Visser D, Langeslag M, Kedziora KM, Klarenbeek J, Kamermans A, Horgen FD, Fleig A, van Leeuwen FN and Jalink K. TRPM7 triggers Ca2+ sparks and invadosome formation in neuroblastoma cells. Cell calcium. 2013; 54:404-415.
63. Linder S. Invadosomes at a glance. Journal of cell science. 2009; 122:3009-3013.
64. Sathornsumetee S and Rich JN. Designer therapies for glioblastoma multiforme. Annals of the New York Academy of Sciences. 2008; 1142:108-132.
65. Sunayama J, Matsuda K, Sato A, Tachibana K, Suzuki K, Narita Y, Shibui S, Sakurada K, Kayama T, Tomiyama A and Kitanaka C. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of selfrenewal and tumorigenicity of glioblastoma stem-like cells. Stem Cells. 2010; 28:1930-1939.
66. Wang J, Liao QJ, Zhang Y, Zhou H, Luo CH, Tang J, Wang Y, Tang Y, Zhao M, Zhao XH, Zhang QY and Xiao L. TRPM7 is required for ovarian cancer cell growth, migration and invasion. Biochemical and biophysical research communications. 2014; 454:547-553.
67. Yu M, Huang C, Huang Y, Wu X, Li X and Li J. Inhibition of TRPM7 channels prevents proliferation and differentiation of human lung fibroblasts. Inflammation research: official journal of the European Histamine Research Society [et al]. 2013; 62:961-970.
68. Meng X, Cai C, Wu J, Cai S, Ye C, Chen H, Yang Z, Zeng H, Shen Q and Zou F. TRPM7 mediates breast cancer cell migration and invasion through the MAPK pathway. Cancer letters. 2013; 333:96-102.
69. Fang L, Zhan S, Huang C, Cheng X, Lv X, Si H and Li J. TRPM7 channel regulates PDGF-BB-induced proliferation of hepatic stellate cells via PI3K and ERK pathways. Toxicology and applied pharmacology. 2013; 272:713-725.
70. Yang YR, Follo MY, Cocco L and Suh PG. The physiological roles of primary phospholipase C. Advances in biological regulation. 2013; 53:232-241.
71. Deason-Towne F, Perraud AL and Schmitz C. Identification of Ser/Thr phosphorylation sites in the C2-domain of phospholipase C gamma2 (PLCgamma2) using TRPM7-kinase. Cellular signalling. 2012; 24:2070-2075.
72. Chen WL, Huang XQ, Zhao LY, Li J, Chen JW, Xiao Y, Huang YY, Liu J, Wang GL and Guan YY. Involvement of Kv1.5 protein in oxidative vascular endothelial cell injury. PloS one. 2012; 7:e49758.
73. Chen WL, Qian Y, Meng WF, Pang JY, Lin YC, Guan YY, Chen SP, Liu J, Pei Z and Wang GL. A novel marine compound xyloketal B protects against oxidized LDLinduced cell injury in vitro. Biochemical pharmacology. 2009; 78:941-950.
74. Goldberg L and Kloog Y. A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer research. 2006; 66(:11709-11717.